Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invitae Corporation Common Stock (NY:NVTA)

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Feb 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invitae Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Invitae Shares Surge On Cathie Wood Comments: Here's What The Ark Invest CEO Said
Invitae Corp (NYSE: NVTA) shares are taking off in Thursday's after-hours session after Ark Invest's Cathie Wood discussed the name on CNBC's " 
Via Benzinga
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Monday, 3/31, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
A Look Into Invitae's Debt
 
Via Benzinga
Invitae's Return On Capital Employed Insights
 
Via Benzinga
Why Invitae Corporation Shares Are Falling Today
Invitae Corporation (NYSE: NVTA) shares are trading lower this Wednesday after the company reported fourth-quarter financial results and provided guidance for full-year 2023. The company also announced... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Invitae (NVTA) Q4 2022 Earnings Call Transcript
NVTA earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Is It Too Late to Buy Invitae Stock?
The stock has been off to a red-hot start in 2023. 
Via The Motley Fool
Invitae Stock: Approach With Caution
The company's $350 million question mark could overshadow recent progress. 
Via The Motley Fool
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Down 78% in 1 Year, Is There Any Hope Left for Invitae?
It doesn't look good, but the company isn't doomed just yet. 
Via The Motley Fool
If You Invested $10,000 in Invitae in 2018, This Is How Much You Would Have Today
Has the stock become a better buy today? 
Via The Motley Fool
Invitae's Debt Overview
Over the past three months, shares of Invitae Inc. (NYSE:NVTA) moved lower by 13.23%. Before having a look at the importance of debt, let's look at how much debt Invitae has. 
Via Benzinga
Invitae Stock: Bull vs. Bear
The bears have prevailed with Invitae this year. But could the future be better for the beaten-down stock? 
Via The Motley Fool
Is Invitae in Danger of Running Out of Money?
The company's cash burn is improving, but it's still troubling. 
Via The Motley Fool
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
The 7 Best Stocks to Short This Week
For those that want to live extremely dangerously, these questionable companies may represent stocks to short this week. 
Via InvestorPlace
HR Tech Spinout Performica Closes on its Seed Round
The technology company raised $3 million in its initial round of funding led by Surface VC and Bowery Capital 
Via Newsworthy
Topics Economy
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
InVitae's 'Long, Uncertain Path' Toward Profitability: Analyst Downgrades Biotech
Shares of Invitae Corp (NYSE: NVTA) came under pressure on Monday, after gaining more than 24% in January. Despite having a restricting plan in place, the biotech company has a “long path to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
 
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor publishes her daily transactions. She keeps buying Tesla as well as some low-priced genetics specialists. 
Via The Motley Fool
3 Growth Stocks That Haven't Been This Cheap in Years
After taking a beating last year, is now the time to load up on these stocks? 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket
Gainers ADC Therapeutics SA (NASDAQ: ADCT) shares rose 36.8% to $4.35 in pre-market trading. ADC Therapeutics and Sobi announced European Commission approval of ZYNLONTA for the treatment of relapsed... 
Via Benzinga
Which Is the Better Buy: Vertex or Invitae?
Is Vertex worth its lofty valuation compared to Invitae? 
Via The Motley Fool
Looking Into Invitae's Recent Short Interest
Invitae's (NYSE:NVTA) short percent of float has fallen 3.57% since its last report. The company recently reported that it has 46.47 million shares sold short, which is 21.59% of all regular shares... 
Via Benzinga
Why PagSeguro Digital Shares Are Trading Lower By 18%? Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Cosmos Holdings Inc. (NASDAQ: COSM) rose 68% to $0.5500 after surging around 87% on Tuesday. Cosmos Holdings recently posted a Q3 loss of $0.08 per share. 
Via Benzinga
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. 
Via Benzinga
Why Shares of Invitae Rose 11% on Tuesday
Investors continue to be encouraged by the company's cost-cutting attempts. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.